Compare
BioAge Labs, Inc. vs Precigen, Inc. vs Prothena Corp Public Ltd Co vs Roivant Sciences Ltd.
| Latest fiscal year | BioAge Labs, Inc. BIOA | Precigen, Inc. PGEN | Prothena Corp Public Ltd Co PRTA | Roivant Sciences Ltd. ROIV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $8.99M | $9.68M | $9.68M | $8.26M |
| Revenue growth (YoY) | n/a | +146.7% | -92.8% | -71.6% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | -896.1% | n/m | n/m | n/m |
| Net income | -$80.61M | -$250.64M | -$244.09M | -$299.77M |
| EPS (Diluted) | -$2.24 | -$1.37 | -$4.53 | -$0.54 |
| Operating cash flow | -$81.63M | -$87.83M | -$163.58M | -$750.35M |
| Free cash flow | -$82.35M | -$89.83M | n/a | -$758.56M |
| Cash & equivalents | $188.89M | $30.23M | $307.53M | $1.42B |
| Total assets | $294.89M | $155.50M | $326.80M | $5.71B |
| Total liabilities | $22.84M | $134.59M | $46.33M | $416.27M |
| Shareholders' equity | $272.05M | $20.91M | $280.47M | $4.53B |
| Return on year-end equity | -29.6% | n/m | -87.0% | -6.6% |
| Shares outstanding | 37.39M | 353.91M | 53.83M | 720.35M |
Revenue, most recent five fiscal years
| Fiscal year | BioAge Labs, Inc. | Precigen, Inc. | Prothena Corp Public Ltd Co | Roivant Sciences Ltd. |
|---|---|---|---|---|
| Latest | $8.99M Ended 2025-12-31 | $9.68M Ended 2025-12-31 | $9.68M Ended 2025-12-31 | $8.26M Ended 2026-03-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $3.92M Ended 2024-12-31 | $135.16M Ended 2024-12-31 | $29.05M Ended 2025-03-31 |
| 2 years earlier | n/a | $6.22M Ended 2023-12-31 | $91.37M Ended 2023-12-31 | $32.71M Ended 2024-03-31 |
| 3 years earlier | n/a | $26.91M Ended 2022-12-31 | $53.91M Ended 2022-12-31 | $31.53M Ended 2023-03-31 |
| 4 years earlier | n/a | $14.27M Ended 2021-12-31 | $200.58M Ended 2021-12-31 | $55.29M Ended 2022-03-31 |